hyS110

hyS110 is a preclinical surrogate bispecific T-cell engager (BiTE) molecule developed by Micromet (later acquired by Amgen) to study the pharmacokinetics, biodistribution, and immunological mechanisms of BiTE constructs in animal models. It consists of two single-chain variable fragments (scFv) connected by a short linker, with one arm targeting murine CD3ε (with a dissociation constant KD of 2.9 nM) and the other arm targeting human epithelial cell adhesion molecule (EpCAM). Because human and murine variants of EpCAM and CD3 are not cross-reactive, hyS110 serves as a key control or surrogate in immunocompetent mouse models to evaluate the specific contribution of the CD3-targeting arm to the overall biodistribution and tissue uptake of BiTE molecules, particularly in lymphoid organs like the spleen and mesenteric lymph nodes.

Other names

89Zr-hyS110[89Zr]Zr-DFO-N-suc-hyS110hyS110 BiTEhyS-110 BiTEhyS 110 BiTEhyS110 BiTE moleculehyS-110 BiTE moleculehyS 110 BiTE molecule